The Sinai Center for Thrombosis Research (SCTR) , under the direction of Paul A. Gurbel, M.D., is recognized in the international cardiology and thrombosis community as a leader in the field of antithrombotic therapy. The expertise of the lab is centered on anti-platelet drug development, antithrombotic therapy and personalized anti-platelet therapy.
The breakthrough findings of Gurbel and his team at Sinai have been published in hundreds of peer-reviewed medical journal articles and have influenced treatment guidelines related to anti-platelet therapy as recognized by the American Heart Association (AHA), the American College of Cardiology and the European Society of Cardiology. Their research has also created a platform for the discovery of new antithrombotic drugs.
Gurbel and his team work with top pharmaceutical and medical device companies that seek their expertise
“As an individual interested in platelet research, I have the privilege to work in conjunction with Dr. Gurbel in different projects here in Brazil, where he is an active member of our “ANTS” (ANTiplatelet Study group) and in the USA. I have seen firsthand how Dr. Gurbel’s research has impacted the care of cardiac patients. His research helped to shape AHA and American College of Cardiology treatment guidelines. I am excited to see how Dr. Gurbel’s research will continue to revolutionize the risk stratification and treatment of cardiac patients.”
José C. Nicolau, M.D., Ph.D.
Professor, University of São Paulo
Medical School Director, Acute Coronary Disease Unit,
Heart Institute (InCor) - University of São Paulo Medical School, São Paulo, Brazil
In this video Dr. Gurbel discusses his interest in thrombosis research:
In this WBAL-Know Your Health radio clip, Dr. Paul Gurbel discusses common sense steps that anyone can take to improve their heart health.
The Sinai Center for Thrombosis Research
Sinai Hospital of Baltimore
2401 West Belvedere Avenue
Baltimore, MD 21215